Search results for "Naphthalene"

showing 10 items of 267 documents

Discovery and characterization of two novel CB1 receptor splice variants with modified N-termini in mouse

2017

Numerous studies have been carried out in the mouse model, investigating the role of the CB1 cannabinoid receptor. However, mouse CB1 (mCB1) receptor differs from human CB1 (hCB1) receptor in 13 amino acid residues. Two splice variants, hCB1a and hCB1b, diverging in their amino-termini, have been reported to be unique for hCB1 and, via different signaling properties, contribute to CB1 receptor physiology and pathophysiology. We hypothesized that splice variants also exist for the mCB1 receptor and have different signaling properties. On murine hippocampal cDNA, we identified two novel mCB1 receptor splice variants generated by splicing of introns with 117 bp and 186 bp in the N-terminal dom…

0301 basic medicineMorpholinesRNA SplicingBiologyNaphthalenesBiochemistryHippocampusArticle5-HT7 receptor03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineReceptor Cannabinoid CB1Cannabinoid receptor type 2Enzyme-linked receptorAnimalsHumanssplice5-HT5A receptorRNA MessengerReceptorMice KnockoutNeuronsMolecular biologyBenzoxazinesRetinoic acid receptorAlternative Splicing030104 developmental biologyHEK293 CellsInterleukin-21 receptor030217 neurology & neurosurgeryEndocannabinoidsSignal Transduction
researchProduct

Cellular mechanisms of IL-17-induced blood-brain barrier disruption.

2009

Recently T-helper 17 (Th17) cells were demonstrated to disrupt the blood-brain barrier (BBB) by the action of IL-17A. The aim of the present study was to examine the mechanisms that underlie IL-17A-induced BBB breakdown. Barrier integrity was analyzed in the murine brain endothelial cell line bEnd.3 by measuring the electrical resistance values using electrical call impedance sensing technology. Furthermore, in-cell Western blots, fluorescence imaging, and monocyte adhesion and transendothelial migration assays were performed. Experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6 mice. IL-17A induced NADPH oxidase- or xanthine oxidase-dependent reactive oxygen species (ROS)…

1303 BiochemistryEncephalomyelitisOccludin10263 Institute of Experimental ImmunologyBiochemistryMice0302 clinical medicineEnzyme InhibitorsCell Line Transformed0303 health sciencesMice Inbred BALB CNADPH oxidasebiologyTight junctionExperimental autoimmune encephalomyelitisInterleukin-17AzepinesT-Lymphocytes Helper-InducerCell biologyEndothelial stem cellBlood-Brain Barrier1305 BiotechnologyBiotechnologyXanthine OxidaseMyosin light-chain kinaseEncephalomyelitis Autoimmune ExperimentalDown-Regulation610 Medicine & healthNaphthalenes03 medical and health sciences1311 GeneticsOccludinGeneticsmedicine1312 Molecular BiologyAnimalsMolecular BiologyMyosin-Light-Chain KinaseNeuroinflammation030304 developmental biologyEndothelial CellsMembrane ProteinsNADPH Oxidasesmedicine.diseaseMolecular biologyAntibodies NeutralizingOxidative Stressbiology.protein570 Life sciences; biologyReactive Oxygen Species030217 neurology & neurosurgeryFASEB journal : official publication of the Federation of American Societies for Experimental Biolog
researchProduct

CCDC 1437668: Experimental Crystal Structure Determination

2015

Related Article: M. Akhazzane, G. Al Houari, M. El Yazidi, M. Saadi, L. El Ammari|2015|Acta Crystallogr.,Sect.E:Cryst.Commun.|71|o981|doi:10.1107/S2056989015022033

4'-(4-methoxyphenyl)-44-dimethyl-3'-(4-methylphenyl)-34-dihydro-1H4'H-spiro[naphthalene-25'-[12]oxazol]-1-oneSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: The PAUSE study

2014

Abstract Background Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. Objective To characterize the safety profile of dapoxetine in PE treatment and to report the incidence, severity, and type of adverse events. Design, setting, and participants We conducted a 12-wk, open-label, observational study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled, with 6712 patients (67.6%) treated with dapoxetine 30–60mg (group A)and 3316 (32.4%) treated with alternative care/nondapoxetine (group B). …

AdultComplementary TherapiesMalemedicine.medical_specialtyBenzylaminesAdolescentNauseaUrologyNaphthalenesDapoxetine Safety Cardiovascular events SyncopeSyncopeCardiovascular eventsYoung AdultInternal medicinePremature ejaculationmedicine80 and overCardiovascular events; Dapoxetine; Safety; Syncope; Adolescent; Adult; Aged; Aged 80 and over; Benzylamines; Complementary Therapies; Humans; Male; Middle Aged; Naphthalenes; Premature Ejaculation; Prospective Studies; Serotonin Uptake Inhibitors; Young AdultHumansProspective StudiesPremature EjaculationAdverse effectProspective cohort studyCardiovascular events; Safety; DapoxetineAgedCardiovascular events; Dapoxetine; Safety; Syncope; UrologyAged 80 and overSertralinebusiness.industrySettore MED/24 - UROLOGIAIncidence (epidemiology)Cardiovascular events; Dapoxetine; Safety; Syncope; Adolescent; Adult; Aged; Aged 80 and over; Benzylamines; Complementary Therapies; Humans; Male; Middle Aged; Naphthalenes; Premature Ejaculation; Prospective Studies; Serotonin Uptake Inhibitors; Young Adult; UrologyMiddle AgedDapoxetineCardiovascular events; Dapoxetine; syncope; SafetyDapoxetineAnesthesiaSerotonin Uptake InhibitorsObservational studymedicine.symptomSafetybusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugCardiovascular events Dapoxetine Safety Syncope
researchProduct

Premature ejaculation: Pharmacotherapy vs group psychotherapy alone or in combination

2017

Objectives: Premature Ejaculation (PE), the commonest sexual dysfunction in males, is generally treated with local anesthetic and SSRI (Dapoxetine). The aim of our study was investigate Group Psychotherapy as an alternative treatment for PE and compare the efficacy of pharmacological treatment and psychotherapy, either alone or in combination, in terms of response and improved Quality of Life (QoL). From a male outpatient population screened for PE, those who received a diagnosis of PE were proposed for the study, enrolled and divided into 3 groups (A, B and C). Each group was treated with Dapoxetine, Group Psychotherapy alone and Dapoxetine and Group Psychotherapy, respectively. Materials …

AdultMaleBenzylaminesmedicine.medical_specialtyEjaculationUrologymedicine.medical_treatmentPopulation030209 endocrinology & metabolismNaphthaleneslcsh:RC870-923Settore MED/24 - UrologiaGroup psychotherapyYoung Adult03 medical and health sciences0302 clinical medicineQuality of lifeGroup psychotherapyInternal medicinePremature ejaculationHumansMedicineeducationPsychiatryAgedPremature ejaculationeducation.field_of_studybusiness.industryMiddle Agedlcsh:Diseases of the genitourinary system. UrologyDapoxetineCombined Modality TherapyPsychotherapyDapoxetineSexual therapySexual dysfunctionPsychotherapy GroupAnxietymedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugArchivio Italiano di Urologia e Andrologia
researchProduct

German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection

1996

Summary One–hundred and ninety–five patients with toenail tinea unguium were recruited to a multicentre double–blind clinical trial. Patients were given 250mg terbinafine or 200 mg itraconazole daily for 12 weeks, with follow–up for a further 40 weeks. At the end of the study, mycological cure rates were 81% (70/86 assessed) for terbinafine and 63% (53/84 assessed) for itraconazole (two–tailed, P < 0·05). The length of unaffected nail was 9·44 mm in the terbinafine group and 7·85 mm in the itraconazole group (two–tailed, P < 0·05). Patient self–assessment also favoured terbinafine, with 65% evaluating it as good to very good, compared with 58% for itraconazole. Before treatment the terbinaf…

AdultMalemedicine.medical_specialtyAntifungal AgentsItraconazoleDermatologyNaphthalenesDouble blindDouble-Blind MethodOnychomycosismedicineHumansTerbinafineAgedbusiness.industryTinea PedisTinea unguiumMiddle AgedDermatologyClinical trialmedicine.anatomical_structurePatient SatisfactionNail (anatomy)TerbinafineFemaleItraconazoleTinea InfectionbusinessFollow-Up Studiesmedicine.drugBritish Journal of Dermatology
researchProduct

Compliance to therapy with Dapoxetine in patients affected by Premature Ejaculation

2012

Introduction Premature ejaculation (PE) is a sexual dysfunction with high prevalence. According to some reports, it is present in about 20-30% of the male population. Since 2009 PE has been treated with a novel inhibitor of serotonin re-uptake, Dapoxetine, which has been reported to be specifically active for PE. Materials and Methods 59 patients have been selected among the patients affected by PE observed at the outpatient department of Urology and Andrology of the “Paolo Giaccone” University Policlinic Hospital of Palermo. Diagnosis was confirmed unequivocally in all patients, who were suitable for drug treatment and accepted to participate in the study. They were divided in 2 groups: on…

AdultMalemedicine.medical_specialtyBenzylaminespremature ejaculation dapoxetine Cytalopram compliance side effectsAdolescentGastrointestinal DiseasesMigraine DisordersComorbidityCitalopramCitalopramNaphthalenesMedication AdherenceSettore MED/24 - UrologiaDrug treatmentYoung AdultInternal medicineSurveys and QuestionnairesPremature ejaculationmedicineOutpatient clinicHumansIn patientPremature EjaculationEiaculazione precoce dapoxetina citalopram compliance effetti collateraliLife StyleAgedGynecologyHigh prevalencebusiness.industryGeneral MedicineMiddle AgedPatient Acceptance of Health CareDapoxetineSexual dysfunctionmedicine.symptomNervous System DiseasesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: study on electrophysiological and behavioral mod…

2015

A growing bulk of evidence suggests that cannabinoid system plays a pivotal role in the control of hyperexcitability phenomena. Notwithstanding, the anticonvulsant action of cannabinoids has not been fully addressed, in particular the involvement of potential cellular neuromodulators, for instance nitric oxide. In the current study, we focused on two distinct rat models of temporal lobe epilepsy, the Maximal Dentate Activation and the pilocarpine-induced acute seizures, providing both electrophysiological and behavioral data on cannabinoid and nitrergic system interplay. We evaluated the antiepileptic effects of WIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4- morpholinylmethyl) pyrrolo[1,…

AgonistAM251MaleCannabinoid receptorIndazolesmedicine.drug_classmedicine.medical_treatmentMorpholinesHippocampusPharmacologyNaphthalenesNitric OxideHippocampusSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1medicineAnimalshippocampus temporal lobe epilepsy cannabinoids behavior percentage of protection electrophysiology.Rats WistarWIN 55212-2Cannabinoid Receptor AgonistsDose-Response Relationship DrugCannabinoidsGeneral NeurosciencePilocarpinemedicine.diseaseEndocannabinoid systemBenzoxazinesRatsDisease Models AnimalEpilepsy Temporal LobePyrazolesCannabinoidNitric Oxide SynthasePsychologyNeurosciencemedicine.drug
researchProduct

Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat.

2009

The anticonvulsant effect of cannabinoids (CB) has been shown to be mediated by the activation of the CB(1) receptor. This study evaluates the anticonvulsant activity of (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN55,212-2, CB agonist) alone or preceded by the administration of N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, selective CB(1) antagonist) in an experimental in vivo model of complex partial seizures (maximal dentate gyrus activation - MDA) in the rat. WIN55,212-2 (21mgkg(-1)) exerted an anticonvulsant effect, significantly reduced by the pre-treatme…

AgonistAM251Malemedicine.medical_specialtyCannabinoid receptormedicine.drug_classmedicine.medical_treatmentMorpholinesNaphthalenesSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1Internal medicineControlCannabinoid Receptor ModulatorsmedicineAnimalsRats WistarReceptorEpilepsyChemistryCannabinoidsGeneral NeuroscienceAntagonistBrainmedicine.diseaseCalcium Channel BlockersElectric StimulationBenzoxazinesRatsDisease Models AnimalMaximal dentate activationAnticonvulsantEndocrinologySettore BIO/14 - FarmacologiaRatPyrazolesAnticonvulsantsCannabinoidEpilepsies Partialmedicine.drugNeuroscience letters
researchProduct

Effects of Cannabinoid Exposure during Adolescence on the Conditioned Rewarding Effects of WIN 55212-2 and Cocaine in Mice: Influence of the Novelty-…

2016

Adolescent exposure to cannabinoids enhances the behavioural effects of cocaine, and high novelty-seeking trait predicts greater sensitivity to the conditioned place preference (CPP) induced by this drug. Our aim was to evaluate the influence of novelty-seeking on the effects of adolescent cannabinoid exposure. Adolescent male mice were classified as high or low novelty seekers (HNS and LNS) in the hole-board test. First, we evaluated the CPP induced by the cannabinoid agonist WIN 55212-2 (0.05 and 0.075 mg/kg, i.p.) in HNS and LNS mice. Then, HNS and LNS mice were pretreated i.p. with vehicle, WIN 55212-2 (0.1 mg/kg), or cannabinoid antagonist rimonabant (1 mg/kg) and were subsequently con…

AgonistMaleArticle Subjectmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectMorpholinesConditioning ClassicalPharmacologyNaphthaleneslcsh:RC321-57103 medical and health sciencesMice0302 clinical medicineRimonabantCocaineRewardmedicineAnimalslcsh:Neurosciences. Biological psychiatry. Neuropsychiatrymedia_commonCannabinoid Receptor AgonistsAddictionAntagonistNovelty seekingCannabinoid Receptor AgonistsConditioned place preference030227 psychiatryBenzoxazinesNeurologyExploratory BehaviorNeurology (clinical)CannabinoidPsychologyCorrigendum030217 neurology & neurosurgeryResearch Articlemedicine.drugNeural plasticity
researchProduct